Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the ...

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: When was the last time you recovered money for shareholders?

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro ...

Stifel Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) an “unexpected move.” The firm says that while it wants to be ...

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year ...